LAG3 and B-cell chronic lymphocytic leukemia: Altogether, these data indicate that LAG-3 may have a co-inhibitory activity in the regulation of cytokine production by T cells in CLL and LAG-3 blockade with relatlimab may, at least partially, restore this crippled T cell-mediated immune response.